In This Article:
As global markets navigate a landscape marked by rising inflation and cautious monetary policies, U.S. stock indexes edge toward record highs with growth stocks outpacing their value counterparts. In this context, companies with high insider ownership can offer unique insights into potential growth trajectories, as insiders often have a vested interest in the company's success and are typically well-informed about its prospects.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 50.1% |
| Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Pricol (NSEI:PRICOLLTD) | 25.4% | 25.2% |
| Laopu Gold (SEHK:6181) | 36.4% | 38.5% |
| Plenti Group (ASX:PLT) | 12.7% | 120.1% |
| HANA Micron (KOSDAQ:A067310) | 18.3% | 119.4% |
| Fulin Precision (SZSE:300432) | 13.6% | 71% |
| Findi (ASX:FND) | 35.8% | 118.4% |
Here's a peek at a few of the choices from the screener.
M31 Technology
Simply Wall St Growth Rating: ★★★★★★
Overview: M31 Technology Corporation offers silicon intellectual property design services within the integrated circuit industry and has a market cap of NT$33.11 billion.
Operations: The company's revenue primarily comes from its Semiconductor Equipment and Services segment, amounting to NT$1.67 billion.
Insider Ownership: 27.2%
M31 Technology is poised for significant growth with forecasted earnings expansion of 47.89% annually, outpacing the TW market's 17.9% growth rate. Despite a volatile share price and declining profit margins from 30.2% to 17.5%, its revenue is expected to grow at an impressive 21.7% per year, surpassing the market average of 11.3%. The company recently participated in high-profile industry events, indicating active engagement with investors and stakeholders in Taiwan.
Healios K.K
Simply Wall St Growth Rating: ★★★★★☆
Overview: Healios K.K. is involved in the research, development, manufacture, and sale of cell therapy and regenerative medicine products across Japan, Europe, and the United States with a market cap of ¥37.96 billion.
Operations: Revenue Segments (in millions of ¥): null
Insider Ownership: 31.7%
Healios K.K. is positioned for robust growth, with revenue projected to increase by 35.7% annually, significantly outpacing the JP market's 4.2%. Despite current unprofitability and a volatile share price, the company is advancing its eNK cell therapy through strategic alliances and private placements totaling ¥1.95 billion. These initiatives are expected to enhance Healios' capabilities in regenerative medicine, supported by collaborations with prominent investors like Athos Capital Limited and OrbiMed Advisors LLC.